Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals

Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System).

Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.

As part of the deal, Noven will grant Actavis a non-exclusive, royalty-bearing license to market its generic Daytrana starting from 01 September 2015, or earlier under certain circumstances.

 Reference: Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals

Comments

comments